Apaziquone for Nonmuscle Invasive Bladder Cancer
Apaziquone is an interesting drug for intravesical use in patients with nonmuscle invasive bladder cancer; however, more research is needed to prove its actual benefit. Although the apaziquone trials demonstrate the potential of this new drug, the singular phase 3 trials did not reach their primary endpoint. To date, no new trials are recruiting, so the development of apaziquone seems to have stopped.
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Tom J.H. Arends, Johannes Alfred Witjes Source Type: research